ストックスクリーナーアプリを入手
2.59
14.60%
0.33
アフターアワーズ：
2.55
-0.04
-1.54%
Clearmind Medicine Inc (CMND) 最新ニュース
Clearmind Medicine Advances Cmnd-100 Phase I/Ii Clinical Trial to Next Parts - marketscreener.com
Clearmind receives Johns Hopkins IRB approval for trial parts By Investing.com - Investing.com Nigeria
Clearmind Medicine stock gains on Johns Hopkins trial approval By Investing.com - Investing.com Canada
Clearmind Medicine stock gains on Johns Hopkins trial approval - Investing.com
Clearmind receives Johns Hopkins IRB approval for trial parts - Investing.com
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts - The Manila Times
Clearmind Medicine Inc. Receives IRB Approval for Phase I/II Clinical Trial of CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Cash from financing activities of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Net income before discontinued operations of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Clearmind Medicine Inc. Balance Sheet – LS:A427B1 - TradingView
Price to earnings ratio of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Clearmind Medicine Inc. Dividends – LS:A427B1 - TradingView
Clearmind Medicine Inc. Earnings and Revenue – LS:A427B1 - TradingView
CMND News | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Will Clearmind Medicine (NASDAQ:CMND) Spend Its Cash Wisely? - Sahm
Clearmind Medicine to implement 1-for-10 reverse share split - MSN
Clearmind Medicine stock tumbles on reverse share split plan By Investing.com - Investing.com Nigeria
Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings - Benzinga
Clearmind Medicine stock tumbles on reverse share split plan - Investing.com
Clearmind Medicine to implement 1-for-10 reverse stock split By Investing.com - Investing.com South Africa
they’re doing it for the hell of it. - Moomoo
Clearmind Medicine to implement 1-for-10 reverse stock split - Investing.com
Clearmind Medicine Inc. Announces 1-for-10 Reverse Share Split to Regain Nasdaq Compliance - Quiver Quantitative
Clearmind Medicine announces 1-for-10 reverse share split - marketscreener.com
Clearmind Medicine Announces 1-for-10 Reverse Share Split - The Manila Times
Clearmind Medicine Announces 1-For-10 Reverse Share Split - TradingView
CMND Stock Price, Quote & Chart | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
$Clearmind Medicine (CMND.US)$[Lol][Lol][Lol] - Moomoo
Clearmind signs research deal to study obesity drug combination By Investing.com - Investing.com Australia
Clearmind signs research deal to study obesity drug combination - Investing.com UK
Tirzepatide Combination Study Expands Clearmind’s Obesity Therapy Strategy (CMND) - Yahoo Finance
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications - The Manila Times
Clearmind Medicine Inc. And Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Sign Agreement To Examine MEAI In Combination And Sequencing With Tirzepatide - marketscreener.com
Clearmind Medicine CEO Dr. Adi Zuloff-Shani Participates in Psychedelic Medicine Coalition Federal Policy Summit - Quiver Quantitative
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. - The Manila Times
Number of shareholders of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
TradingKey - TradingKey
Clearmind doses two more patients in alcohol disorder trial - Investing.com UK
Clearmind Medicine Treats 20 Participants in CMND-100 Alcohol Use Disorder Trial - geneonline.com
20 patients treated in Clearmind (Nasdaq: CMND) Phase I/IIa AUD study - Stock Titan
Clearmind doses two more patients in alcohol disorder trial By Investing.com - Investing.com Nigeria
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - The Manila Times
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing ... - Caledonian Record
Novel non-hallucinogenic alcohol use disorder drug reaches 20 patients - Stock Titan
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):